News & Events
News
Oslo University Hospital announces the startup of a multicentre randomized phase 2 trial of ILB® in ALS, commencing early 2026. The study will compare ILB® to Riluzole, the current standard of care, and will include 116 patients over a 12-month study period.
Senior consultant neurologist Dr Angelina Hatlø Maniaol is coordinating investigator for the study, which will consist of a 6-month double-blind randomized phase where patients will get either Riluzole or ILB®, followed by a 6-month open-label extension where patients will get both ILB® and Riluzole. The study is sponsored by Oslo
TikoMed elects a new Board of Directors – Annika Kollén and Anders Svensson join the board
At the Annual General Meeting on 30 June 2025, TikoMed elected a new board of directors for the period until the next general meeting. The three members of the interim board elected in April this year will continue their assignments – Göran Groth as Chairman of the Board and Tobhias
TikoMed väljer ny styrelse – Annika Kollén och Anders Svensson in i styrelsen
Vid den ordinarie bolagsstämman den 30 juni 2025 valde TikoMed en ny styrelse för tiden fram till nästa bolagsstämma. De tre ledamöterna från interimsstyrelsen som valdes i april månad fortsätter sina uppdrag – Göran Groth som styrelseordförande och Tobhias Brandell och Lars Bruce som styrelseledamöter. Utöver dessa valde stämman in
TikoMed announces the publication of results from an open-label, single arm, single center phase II trial carried out at the Queen Elizabeth Hospital, Birmingham, UK, by the University of Birmingham’s Drugs, Devices, Diagnostics and Biomarkers (D3B) team in patients with confirmed Amyotrophic Lateral Sclerosis (ALS) treated with weekly ILB® injections.
Viken, Sweden July 22nd, 2024: Swedish drug development company TikoMed AB today announced the publication in PLOS ONE of peer-reviewed research providing additional support that their low molecular weight dextran sulfate compound ILB® is safe and well tolerated in patients with ALS. Eleven patients participated in the prospective, single-arm, open-label,
The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed have officially signed a research collaboration agreement.
Oslo, June 25th, 2024. The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed have recently signed a research collaboration agreement. Common ambition for the parties is for their collaboration to lead to more knowledge and better treatment options for patients diagnosed with Amyotrophic
Prominent Italian ALS expert Adriano Chiò joins TikoMed’s Scientific Advisory Board (SAB)
Viken, Sweden – October 25, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Professor Adriano Chiò, of the University of Torino and the Città della Salute e della Scienza Hospital as the fourth member of its newly formed Scientific Advisory Board. Adriano Chiò is a neurologist